Health officials prepare to vaccine residents of Malawi village of Tomali where young children become test subjects for world's first vaccine against malaria.
The World Health Organization (WHO) on Wednesday approved the world's first vaccine for Malaria and recommended its broad use for children, especially across Africa. The move officials hope will spur stalled efforts to curb the spread of the parasitic disease.
Following a meeting of the United Nations health agency’s vaccine advisory group, WHO director-general Tedros Adhanom Ghebreyesus spoke of “a historic moment.”
“Today’s recommendation offers a glimmer of hope for the continent which shoulders the heaviest burden of the disease and we expect many more African children to be protected from malaria and grow into healthy adults,” said Dr. Matshidiso Moeti, the WHO’s Africa director.
The WHO said its decision was based on results from ongoing research in Ghana, Kenya and Malawi that has tracked more than 800,000 children since 2019.
The malaria vaccine known as Mosquirix was developed by GlaxoSmithKline in 1987. While it’s the first to be authorized, it is only about 30% effective, requires up to four doses, and protection fades after just months.
Still, given the extremely high burden of malaria in Africa- where the majority of the world’s more than 200 million cases a year and 400,000 deaths occur- scientists say the vaccine could still have a major impact.
“This is a huge step forward,” said Julian Rayner, director of the Cambridge Institute for Medical Research, who was not part of the WHO decision. “It’s an imperfect vaccine, but it will still stop hundreds of thousands of children from dying.” Rayner said that the vaccine’s impact on the spread of the mosquito-borne disease was still unclear, but pointed to the coronavirus vaccines as an encouraging example.
“The last two years have given us a very nuanced understanding of how important vaccines are in saving lives and reducing hospitalizations, even if they don’t directly reduce transmission.”
Sian Clarke, co-director of the Malaria Centre at the London School of Hygiene and Tropical Medicine, said the vaccine would be a useful addition to other tools against the disease that might have exhausted their utility after decades of use, like bednets and insecticides.
“In some countries where it gets really hot, children just sleep outside, so they can’t be protected by a bednet,” Clarke explained. “So obviously if they’ve been vaccinated, they will still be protected.”
Clarke added that in the last few years little significant progress has been made against malaria. “If we’re going to decrease the disease burden now, we need something else.”
